Navigation Links
Elixir Pharmaceuticals Presents Preclinical Data Highlighting Its,Ghrelin Antagonist Program at the American Diabetes Association's,Annual Meeting

nd debilitating metabolic disorders such as Type 2 diabetes and obesity," stated Peter DiStefano, Ph.D., Chief Scientific Officer. "We are rapidly advancing our EX-1350 ghrelin antagonist and plan to initiate Phase I testing early next year."

According to the International Diabetes Federation, Type 2 diabetes affects 195 million people worldwide, and the number of sufferers could top 330 million by 2025.

Elixir has filed broad intellectual property protection on all aspects of the ghrelin antagonist program including composition of matter protection covering five novel compound classes and their therapeutic uses.

About Elixir Pharmaceuticals

Elixir is a Cambridge, MA-based biopharmaceutical company focused on developing and commercializing drugs to treat and prevent metabolic disease, prevent age-related diseases, ultimately extending the quality and length of human life.

In addition to its ghrelin antagonist program, the Company has leveraged its knowledge of ghrelin biology and pharmacology by licensing a small molecule ghrelin agonist (designated EX-1314) from Bristol-Myers Squibb Company in April 2005. EX-1314 binds selectively to the ghrelin receptor and mimics the body's naturally occurring ghrelin. In doing so this novel, orally available agent is capable of stimulating appetite, gastric motility and the release of growth hormone. Elixir is currently in IND-enabling studies with EX-1314 targeting a variety of therapeutic indications.

Further, in March 2006, Elixir in-licensed North and South American rights to Glufast(R) (mitiglinide calcium hydrate), an insulin secretagogue, which lowers post-meal glucose levels by improving the body's own ability to produce insulin. Already marketed in Japan, Glufast has undergone extensive clinical development demonstrating the product's ability to safely and effectively treat Type 2 diabetes.

Elixir has also developed expertise and a broad IP portfolio of more than twenty p
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Elixir Pharmaceuticals Announces Clinical Data at American Diabetes Association Conference Highlighting Ability of Glufast to Maintain Glycemic Control in Patients with Type 2 Diabetes
2. Elixir Pharmaceuticals Presents Additional Preclinical Data Demonstrating the Potential of Ghrelin Antagonism to Regulate Metabolism, Body Weight and Glycemic Control
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)

Post Your Comments:
(Date:11/30/2009)... N.J., Nov. 30 MedQuist ...ology-enabled clinical documentation services, tod...Nuance Communications, Inc. (Nuance) under which M...ch recognition engine and processing software for ... front-end speech recognition application for all ...
(Date:11/30/2009)...YORK, Nov. 30 Reportlinker.com ann...ble in its catalogue: ,, Diabetes Diagnostics ...eportlinker.com/p0164347/Diabetes-Diagnostics---A-...agnosis market is driven by a steady increase in t...in the developed and developing parts of the world...
(Date:11/30/2009).... 30 Dr. Jocelyn Rapelyea, Associa...George Washington University Medical Center in Was...ntified with Breast-Specific Gamma Imaging (BSGI) ...for needle biopsy as well, as for pre-operative lo...ological Society of North America (RSNA). ,, BS...
Breaking Medicine Technology:MedQuist Signs Agreement Extending Use of Real-Time Speech Recognition Engine to Wide Range of Medical Specialties 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 2Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 3Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 4Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 5Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 6Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 7Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 8Reportlinker Adds Diabetes Diagnostics - A Global Market Perspective 9Breast-Specific Gamma Imaging Identifies Occult Lesions Using Multi-Modality Imaging for Biopsy 2Disability Rates Continue Steady Climb According to CDAs 2008 Disability Claims Review 56752 1Disability Rates Continue Steady Climb According to CDAs 2008 Disability Claims Review 56752 2Disability Rates Continue Steady Climb According to CDAs 2008 Disability Claims Review 56752 3Prime Retail Launches Operation Shop Pink 56749 1Prime Retail Launches Operation Shop Pink 56749 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 1Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 2Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 3Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement 13976 4
...Reported Safety & Tolerability Profile,in Subj... CHICAGO, June 25, 2007 /PRNewswire-FirstCall/ -- ...eeting of the American Diabetes,Association demons...l-peptidase-4 (DPP-4) in development by Bristol-My...n with metformin,exhibited a statistically signif...
...NYVALE, Calif., June 27, 2007,/PRNewswire-FirstCal...ary results from two open-label, multi-center Phas...f Xcytrin(R),(motexafin gadolinium) Injection, the...with Alimta(R) (pemetrexed) and in,combination wit...nt,for patients with non-small cell lung cancer (N...
Other Medicine Technology:Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 2Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 3Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 4Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 5Data Demonstrated Saxagliptin Added to Metformin Improved Glycemic,Control in Subjects with Type 2 Diabetes Compared to Metformin,Alone 6Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 2Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 3Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 4Pharmacyclics Announces Interim Results From Two Ongoing Phase 2,Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat,Recurrent Non-Small Cell Lung Cancer 5
(Date:11/30/2009)...RNewswire/ -- HealthPlus of Michigan today announc... plans designed for Medicare-eligible people looki...ccess to quality health care. ,, HealthPlus Me... in Michigan, according to the "America,s Best Hea... & World Report and the National Committee on ...
(Date:11/30/2009)...or Alonzo L. Fulgham ,, WASHINGTON, Nov. 30 /P...al community once again recognizes World AIDS Day ...ldwide. This is also a time to renew our commitme... and pay homage to the millions of people who have...er in the U.S. President,s Emergency Plan for AIDS...
(Date:11/30/2009)...ewswire/ -- Major League Baseball,s Mark Teahen,... and recently acquired by the Chicago White Sox, w...d is given annually to a Major League Baseball pla...dication of baseball great Fred Hutchinson, both o...ands, Calif., native made his MLB debut with the R...
(Date:11/30/2009)...ent for blood-borne diseases, researchers say , ... medical students get stuck by needles, putting th...n fail to alert hospital authorities, which increa.... , The researchers interviewed 699 surgery res... 59 percent -- had experienced needlestick injurie...
(Date:11/30/2009)...RNewswire-USNewswire/ -- SEIU Local 21LA members a... Sodexo will hold a rally Tuesday, Dec. 1, 2009, a...arters, 3800 Desire Parkway, New Orleans, to prote...iplinary policies that target employees who are il...dexo employees who clean schools in the Recovery S...
Breaking Medicine News(10 mins):Health News:HealthPlus Launches New Medicare Advantage Plans 2Health News:HealthPlus Launches New Medicare Advantage Plans 3Health News:USAID Recognizes World AIDS Day 2Health News:Mark Teahen Named 2009 Hutch Award Winner 2Health News:Med Students Often Fail to Report Needlestick Injuries 2Health News:As H1NI Hits New Orleans in Force: School Custodians to Hold Rally to Call on Contractor to Stop Penalizing Workers Coping With Illness 2
...hat doing household activities like cleaning the h...prevent hypertension and conditions of prehyperten...rdless of intensity, four hours of accumulated dai... from prehypertensive to normal -- for an average ...
...Electric (GE), Tuesday launched HF Advantage, the ...nd made in India for the domestic and internationa...technology, the state-of-the-art product is equipp...rs at the John F. Welch Technology Centre of GE in...
...a new cheaper tissue culture vaccine for Japanese ...reported 200 deaths and 700 patients with infectio...y year due to the endemic infection of Encephaliti...4 hours, in which 12 persons died. The health ...
... of Wisconsin-Madison had reported that specific b...re affected by stress, like asthma. The study...oceedings of the National Academy of Sciences, // ...ggest potential future targets for the development...
...i may soon become part of the Indian government's ...to spread awareness about HIV/AIDS and promote the...rts have failed in reaching supplies of condoms, t... country. It has been proposed to advertise...
...ovarian cancer, according to a new Danish study, w...sk of some other forms of cancer. Women who ex...uction in the risk of development of ovarian cance...ercise habits of nearly 28,000 men and women, has ...
Other Medicine News:Health News:New X-ray machine launched by GE Healthcare 2
VISCO SHIELD Viscoelastic
Universal I/A handpiece - Stainless steel (Round Handle with Straight Tip)
Infusion Cannula 4.0mm
Subretinal Fluid Cannula Curved
Medicine Products: